Abstract
Consensus practices and regulatory guidance for liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) assays of small molecules are more aligned globally than for any of the other bioanalytical techniques addressed by the Global Bioanalysis Consortium. The three Global Bioanalysis Consortium Harmonization Teams provide recommendations and best practices for areas not yet addressed fully by guidances and consensus for small molecule bioanalysis. Recommendations from all three teams are combined in this report for chromatographic run quality, validation, and sample analysis run acceptance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
European Medicines Agency. Guideline on bioanalytical method validation 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed 26 Jan 2014.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf . Accessed 29 Jan 2014.
Dyson N. Chromatographic integration methods. 2nd ed. London: RSC Chromatography Monographs; 1998. doi:10.1039/9781847550514. 978-0-85404-510-5.
Meyer VR. Error sources in the determination of chromatographic peak ratios. In: Advances in chromatography. New York: Marcel Dekker; 1995. p. 383.
Hill HM, Smeraglia J, Brodie RR, Smith GT. Where do you draw the line? Points to consider when implementing the FDA method validation guidance on quantifying chromatographic peaks. Chromatographia. 2002;55(Suppl):S79–81.
Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. 3rd ed. Hoboken: Wiley; 2010. doi:10.1002/9780470508183. 978-0-470-16754-0.
Garofolo F, Rocci ML, Dumont I, Martinez S, Lowes S, Woolf E, et al. 2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis. 2011;3(18):2081–96.
Ministério da Saúde, Agência Nacional de Vigilância Sanitária, Brazil. RESOLUÇÃO - RDC No 27, DE 17 DE MAIO DE 2012. http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2012/rdc0027_17_05_2012.html . Accessed 29 Jan 2014.
Bergeron M, Bergeron A, Furtado M, Garofolo F. Impact of plasma and whole-blood anticoagulant counter ion choice on drug stability and matrix effects during bioanalysis. Bioanalysis. 2009;1(3):537–48.
Sennbro CJ, Knutsson M, van Amsterdam P, Timmerman P. Anticoagulant counter ion impact on bioanalytical LC-MS/MS assays: results from discussions and experiments within the European Bioanalysis Forum. Bioanalysis. 2011;3(21):2393–99.
Sennbro CJ, Knutsson M, Timmerman P, van Amsterdam P. Anticoagulant counter ion impact on bioanalytical LC-MS/MS assay performance: additional validation required? Bioanalysis. 2011;3(21):2389–91.
World Health Organization. Handbook: good laboratory practice (GLP): quality practices for regulated non-clinical research and development. 2nd ed. Geneva: WHO Special Programme for Research and Training in Tropical Diseases; 2009. 978-92-4-154755-0.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Binodh DeSilva and Philip Timmerman
Rights and permissions
About this article
Cite this article
Woolf, E.J., McDougall, S., Fast, D.M. et al. Small Molecule Specific Run Acceptance, Specific Assay Operation, and Chromatographic Run Quality Assessment: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Teams. AAPS J 16, 885–893 (2014). https://doi.org/10.1208/s12248-014-9633-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9633-4